We’re pleased to share that our LinkedIn community has now surpassed 500 followers!
This growing network reflects the increasing interest in DECISION’s work to improve patient outcomes in decompensated cirrhosis through translational research and clinical trials.

We’re grateful for your continued support and look forward to sharing more updates, results, and opportunities for collaboration in the months ahead.
📲 https://www.linkedin.com/company/decision-project/

After an energizing few days in Amsterdam, we’re back with renewed motivation and important insights from this year’s EASL Congress 2025.

The DECISION team had the pleasure of participating in a number of sessions and meetings – from scientific presentations to networking events and our own investigator meeting. Each encounter reaffirmed the value of collaboration in tackling the complexities of decompensated cirrhosis and ACLF.

Among the highlights:

• → Our Networking Session brought together researchers, clinicians, and project partners to exchange on cutting-edge data – including biomarker discovery and single-cell sequencing.
• → The Investigator Meeting reaffirmed our shared commitment to advancing recruitment and bringing both the COMBAT and PROSPECT studies toward completion.
• → Many poster presentations!

We’re deeply grateful to everyone who engaged with us, supported our sessions, or simply stopped by to learn more about our work. Events like EASL remind us how vital community is to scientific progress.